

Index

- absolute risk reduction (ARR) *see* risk difference
- abstracts 55, 352–5
- adverse effects 441–2
 - non-randomized studies 406
 - Overviews of reviews 615–16
 - searching 98, 110, 143, 145, 406, 441–2
 - selecting studies 153
- accumulation of changes 38
- acknowledgements 68, 624
- ACR *see* assumed control risks
- Additional tables 72, 234, 350–1, 468, 539
- adherence 160, 369
- adverse effects 433–48
- data collection 161–2
 - definitions 434
 - drop-outs 438
 - eligibility criteria 434–8
 - narrow/broad focus 437–8
 - non-randomized studies 397, 400, 427, 438, 443–5
 - review questions 90
 - risk of bias/quality 442–5
 - searching 439–42
 - separate reviews 436–7
 - sources of information 439–40
 - strategies for addressing 434–7
 - Summary of findings tables 348–9
 - types of studies 438, 442–5
- Adverse Effects Methods Group (AEMG) 446
- advisory groups 19–20
- AEMG *see* Adverse Effects Methods Group
- aetiological research questions 399
- agreement measures 155–6, 169
- allied health-specific databases 103–4
- allocation concealment 193, 211, 214–17
- results sections 65
 - Risk of bias tool 196, 198–9, 203–4
- amendments 33, 34–7
- analysing data *see* meta-analysis
- analysis of covariance (ANCOVA) 270
- analysis plans 58, 60–3, 244–6, 564, 565
- prospective meta-analyses 564, 565
- ANCOVA *see* analysis of covariance
- appendices 78
- search strategies 144, 146
- applicability
- discussion sections 66
 - interpreting results 367–9
 - Overviews of reviews 622–3
 - public health and health promotion 601–3
- Applicability and Recommendations Methods Group (ARMG) 383
- ARR (absolute risk reduction) *see* risk difference
- as-treated analyses 225
- assessing a review as up to date 40, 43–4, 54, 625–6
- assumed control risks (ACR) 347, 349, 374, 376–7
- attrition bias 194–6, 200, 219
- authors' conclusions *see* conclusions
- authorship 36, 38, 39, 52–3
- available case analysis 489, 490, 492
- background sections 56–7, 617–18
- baseline imbalance 231–2
- baseline risk *see* control group risk
- Bayesian methods 210, 518–19
- before-and-after studies 393, 596–7
- bias *see* publication bias; reporting bias; risk of bias
- Bias Methods Group (BMG) 324
- bibliographic databases 98–107

- binary outcome data *see* dichotomous outcome data
- biologic variation 368
- biology-specific databases 103
- blinding 193–4, 217–9
 - results sections 65
 - review authors 168, 192, 382
 - Risk of bias tool 195–196, 199, 203–4, 217–19
- blocked randomization 194, 212, 232
- BMG *see* Bias Methods Group
- Boolean operators 132–3, 141
- broad questions 91–3

- Campbell and Cochrane Economics Methods Group (CCEMG) 454, 463, 468, 475, 543
- Campbell Collaboration 147
- Campbell Coordinating Groups 584
- Campbell Equity Methods Group 597–8
- carry-over effects 499–503
- case reports 438, 444–5
- case series 393, 438
- case-control studies 393, 399, 415–16, 438, 443–4
- CBA *see* cost-benefit analysis
- CBT *see* cognitive behavioural therapy
- CCEMG *see* Campbell and Cochrane Economics Methods Group
- CCTs *see* controlled clinical trials
- CDSR *see* Cochrane Database of Systematic Reviews
- CEA *see* cost-effectiveness analysis
- CENTRAL *see* Cochrane Central Register of Controlled Trials
- central randomization 216
- Centre for Reviews and Dissemination (CRD) 111, 460–2, 463
- CGR *see* control group risk
- change scores 172, 269–70
 - standard deviations 485–8
- changing review questions 93
- Characteristics of studies tables 63–4, 70–2
 - economics evidence 468
 - excluded studies 64, 71, 154
 - included studies 63–4, 70, 336–7, 468
 - ongoing studies 64, 72
 - Overviews of reviews 620, 625–6
 - studies awaiting classification 64, 71
- checklists 191
- chi-squared tests 277–8, 281, 284, 338–9

- CINAHL database 103, 579
- citation
 - bias 298, 306
 - indexes 105
 - versions 33–6, 37–9, 55
- citing
 - protocols 58
 - reviews 25–6
- clinical event pathways 455–6
- clinical trials *see* randomized trials
- cluster-allocated studies 409–11
 - see also* cluster-randomized trials
- clustering 498
- cluster-randomized trials 260, 493–8
 - effective sample sizes 495–7
 - inflating standard errors 497
 - meta-analysis 495–6, 497
 - methods of analysis 495
 - public health and health promotion 594, 595, 599
 - risk of bias 494–5
 - sensitivity analyses 291
- CMR *see* Cochrane Methodology Register
- Cochrane, Archie 4, 450
- Cochrane Central Register of Controlled Trials (CENTRAL) 5, 98–100, 108, 118–29, 133, 139–42, 406
- Cochrane Collaboration 3–6
 - maintenance of Cochrane reviews 32
 - preparation of Cochrane reviews 11, 18, 24–8
 - principles 4, 8
 - publication of Cochrane reviews 5–6
 - structure 4–5
- Cochrane Database of Systematic Reviews (CDSR) 5–6
 - citation versions 33–6
 - citing 25–6
 - dates 40, 54–5
 - Overviews of reviews 608
 - prospective meta-analyses 566
 - protocols 12–13, 17
 - searching *see* Cochrane Library
 - withdrawn reviews 46
- Cochrane Health Equity Field 597–8
- Cochrane Library 5
 - Cochrane Review Groups 22–4
 - economics evidence 460–1
 - feedback 48
 - Overviews of reviews 608
 - searching 99–100, 119, 121, 124–6, 133–4
- Cochrane Methodology Register (CMR) 5

- Cochrane Review Groups (CRGs) 4–5, 7
 - economics evidence 453–4
 - guidance and support 17, 20–4, 27, 59, 68, 91
 - maintenance of Cochrane reviews 32, 35, 37–8, 41, 45–6, 48
 - non-randomized studies 398, 399–400, 403, 406–7
 - Overviews of reviews 607–8, 613
 - plain language summaries 355–6
 - prospective meta-analyses 566
 - public health and health promotion 595
 - qualitative research 576, 583–4
 - searching 59–60, 96–8, 102, 108, 118–19, 123–5, 130, 144
 - statisticians 292
- Cochrane reviews
 - Diagnostic test accuracy 7, 20
 - Intervention 6–7, 12–16
 - Methodology 20
 - Overviews of reviews 20, 607–31
- coding schemes 167
- cognitive behavioural therapy (CBT) 536
- cohort studies 393, 399, 415, 438, 443–4
- collaborations
 - individual patient data 549, 550–1
 - prospective meta-analyses 562–3
 - see also* Cochrane Collaboration
- combining studies *see* meta-analysis
- combining subgroups/intervention groups 177
- comments and criticisms *see* feedback
- commercial interests 26–8, 303–4, 624
- community healthcare-specific databases 104
- comparisons 74–5, 86–7, 245, 247–8
- completeness of evidence 66
- concealment of allocation *see* allocation
 - concealment
- conclusions 67, 380–2
 - abstract 353, 355
 - changed 34, 37–8
 - economics evidence 474
 - Overviews of reviews 616, 623–4
 - qualitative research 578
- conditional outcomes 492–3
- conference abstracts/proceedings 110–11
- confidence intervals 369–71
 - continuous outcome data 172–5, 370
 - data extraction 173–5, 181–2
 - dichotomous outcome data 171, 370
 - forest plots 338
 - rare events 522
 - Summary of findings tables 349–50
- confidentiality 550–1, 563
- conflicts of interest *see* declarations of interest
- confounding
 - GRADE/quality of evidence 362, 366
 - heterogeneity 287
 - indirect comparisons 514
 - non-randomized studies 395, 397, 412, 416–17, 420–2, 425–6
 - public health and health promotion 594
- consensus 169
- consistency *see* heterogeneity
- consumer involvement 18–19
- contact persons 53–4
- contents of Cochrane reviews 12–16, 51–79
 - abstracts 55
 - appendices 78
 - data and analyses 74–5
 - feedback 77
 - figures 76–7
 - plain language summaries 55
 - protocol information 52–5
 - review information 52–5
 - studies and references 72–4
 - tables 70–2
 - text 55–70
 - titles 52–3
- context 368–9, 599–600
- continuous outcome data 250, 255–7
 - confidence intervals 172–5, 370
 - counts 179
 - data extraction 171–7, 179
 - forest plots 338–9
 - funnel plots 317–18
 - individual patient data 554, 555
 - intention to treat 491–2
 - interpreting results 377–9
 - meta-analysis 268–72, 290
 - non-randomized studies 421
 - Overviews of reviews 629
 - results sections 338–9, 349, 370, 377–9
 - risk of bias 200, 223–4, 227
 - Summary of findings tables 349
 - see also* patient-reported outcomes
- contour-enhanced funnel plots 313–15
- contributions of authors 68–9
- control group risk (CGR)
 - effect measures 251–3
 - interpreting results 346–7, 349, 374, 377
 - meta-regression 288–9
 - see also* assumed control risk

- controlled
 - before-and-after studies 393
 - vocabulary 130–1, 440, 538–9
- controlled clinical trial (CCT) 119–23, 126
- copyright 97–8
- correlation coefficients 486–8, 496–8, 505–7
- correspondence with investigators 163, 166, 193
- cost data 470–1
- cost-benefit analysis (CBA) 451, 452, 457
- cost-effectiveness analysis (CEA) 451, 452, 457, 472–3
- cost-utility analysis (CUA) 451, 452
- count data 250, 258
 - data extraction 178–9
 - meta-analysis 273–4, 521
 - zero-cell 521
- covariates 284–5, 422
- Cox model 180, 275, 421
- CRD *see* Centre for Reviews and Dissemination
- CRGs *see* Cochrane Review Groups
- critical appraisal
 - qualitative research 580–1, 590–1
 - see also* quality, risk of bias
- cross-over trials 261, 498–508
 - eligibility criteria 499
 - meta-analysis 502–7
 - methods of analysis 501–2
 - risk of bias 499–501
 - sensitivity analyses 291
 - unit of analysis errors 261, 502
- cross-sectional studies 393, 415
- CUA *see* cost-utility analysis
- cultural factors 360, 368–9

- DARE *see* Database of Abstracts of Reviews of Effects
- data
 - collection 156–67
 - abstracts 353, 354
 - economics evidence 462–3, 466
 - forms 164–7
 - individual patient data 551–3
 - interventions 157, 159–60
 - methods of studies 157, 158
 - methods sections 60–3
 - non-randomized studies 407–11
 - outcomes 157, 161–2
 - Overviews of reviews 614, 619
 - participants 157–9
 - prospective meta-analyses 564, 566–7
 - results 157, 162
 - risk of bias 192–3
 - sources of data 157, 163–4
 - sustainability 600
 - entry 170–1, 175, 180–2
 - extraction 167–82
 - consensus 169
 - continuous outcome data 171–7, 179
 - conversion to desired format 170–82
 - counts 178–9
 - dichotomous outcome data 170–1, 179
 - estimates of effects 180–2
 - multiple reports 168–9
 - ordinal outcome data 178
 - Overviews of reviews 619–20
 - results 170–82
 - time-to-event data 179–80
 - management 182–3
 - individual patient data 551–3
 - Overviews of reviews 619–20
 - prospective meta-analyses 564, 566, 567–8
 - synthesis *see* meta-analysis
 - time to event *see* time-to-event data
 - types 249–59
 - see also* continuous outcome data; count data; dichotomous outcome data; ordinal outcome data; rate data; time-to-event data
- Data and analysis section 74–5, 337–41, 351
- Database of Abstracts of Reviews of Effects (DARE) 5, 111
- dates 39–41, 42, 54–5, 134
- declarations of interest 26–8, 69, 624
- derivative products 27
- DerSimonian and Laird method *see* random-effects methods
- descriptions of condition/intervention 57
- design-specific risk of bias 230
- detection bias 195
- diagnostic test accuracy 7
- dichotomous outcome data 249–55
 - confidence intervals 171, 370
 - counts 179
 - data extraction 170–1, 179
 - forest plots 338
 - funnel plots 312, 318–19
 - individual patient data 554, 555
 - intention to treat 490–1
 - interpreting results 372–7
 - meta-analysis 265–8, 271–2, 520–3
 - non-randomized studies 421
 - patient-reported outcomes 541

- risk of bias 200, 208, 223, 227
 - Summary of findings tables 346–7, 349
 - difference measures 181–2, 254, 255–7, 372–7
 - difference in means 255–6, 377–8
 - cross-over trials 503–5
 - funnel plots 317–19
 - meta-analysis 268–72
 - differential diagnostic activity 232
 - directly observed therapy (DOT) 576–9
 - directness *see* indirect evidence
 - discussion sections 66–7, 622–3
 - dissertations databases 106
 - dose-response analyses 289, 362, 367
 - DOT *see* directly observed therapy
 - double-blinding *see* blinding
 - Downs and Black instrument 418
 - drop-outs *see* incomplete outcome data
 - Drummond checklist 465–6
 - duplicated data *see* multiple reports

 - early stopping 231
 - economics evidence 449–79
 - clinical event pathways 455–6
 - data analysis 466–72
 - data collection 462–3, 466
 - eligibility criteria 457–9, 462, 465–6
 - evaluation types 450–3
 - meta-analysis 470–1
 - model development 471–2
 - outcomes 456–7
 - reporting bias 472–3
 - review questions 90, 454–6
 - risk of bias/quality 463–7, 470
 - role and relevance 449–54
 - searching 459–62
 - strategies for addressing 457–9
 - types of evidence 457–9, 463–7, 450–3
 - editorial procedures 21–2, 46
 - education-specific databases 104
 - effect
 - estimates 180–2, 263–5
 - measures 61, 250–9, 279–80
 - modification 282
 - size 256–7
 - Effective Practice and Organisation of Care (EPOC) Group 596
 - effectiveness 399, 597–8
 - Effectiveness and Efficiency* (Cochrane) 450
 - effects of interventions section 65–6
 - Electronic Information for Libraries (eIFL) 99, 109

 - eligibility criteria 84–94, 151–4
 - abstracts 353–4
 - adverse effects 435–8
 - Cochrane Review Groups 22
 - cross-over trials 499
 - data collection 157, 165–6
 - economics evidence 457–9, 462, 465–6
 - excluded studies 154
 - measures of agreement 155–6
 - methods sections 58–9
 - multiple reports 152
 - non-randomized studies 396–403, 407, 425
 - Overviews of reviews 609–12, 614, 618–19, 625
 - prospective meta-analyses 559–61, 564–5
 - qualitative research 577
 - references 73
 - searching 128
 - selection process 151–6
 - sensitivity analyses 290
 - studies versus reports 152
 - unpublished studies 308–9
 - updates and amendments 44
- EMBASE 98–102, 118
 - adverse effects 440–1
 - CENTRAL 121
 - economics evidence 460
 - non-randomized studies 404
 - qualitative research 579
 - reporting bias 305
 - searching for reviews 111–12
 - searching for studies 125–31, 139
 - EPICOT acronym 381
 - EPOC *see* Effective Practice and Organisation of Care
 - EPPI *see* Evidence for Policy and Practice Information
 - errata 37, 38, 134–5
 - estimates of effect *see* effect estimates
 - ethics 234, 597–8
 - Evers checklist 465, 467
 - Evidence for Policy and Practice Information (EPPI) Centre 580, 582, 591
 - excluded studies 154
 - Overviews of reviews 625
 - reporting bias 308–9
 - results sections 64
 - sensitivity analyses 280, 290
 - table 71, 73
 - see also* eligibility criteria

638

exclusions 194, 196, 200, 219–21
see also intention to treat
 explanatory variables 284–5
 external funding 77, 303–4

factorial trials 508, 512–13
 fail-safe N 321–2
 false negatives 283
 false positives 283–4, 318
 feedback 48, 77
 figures 76–7, 341–2
 Overviews of reviews 630
 risk of bias 202–4, 207
see also forest plots; funnel plots
 file drawer problem 299
 first published dates 54
 fixed-effect method 264, 279
 confidence intervals 279, 370
 forest plots 338–9
 reporting bias 319–21
 RevMan 265, 268–9, 275
 sensitivity analyses 291, 319–21
 forest plots 76, 337–40
 figures 341–2
 heterogeneity 277, 284
 non-randomized studies 423–4
 results sections 351
 risk of bias 207
see also forest top plots
 forest top plots 342, 630
 format of Cochrane reviews 12–16
see also contents of Cochrane reviews
 fraudulent studies 134–5
 free-text terms 130–1, 441–2, 539
 full economic evaluations 451–2
 full-text electronic journals 108–9
 full-text reports 153
 functional status 534
 funding
 preparation of Cochrane reviews 24
 risk of bias 233
 funnel plots 310–19
 figures 76, 341
 non-randomized studies 404
 tests for asymmetry 314–19

GDP *see* gross domestic product
 generic inverse-variance outcome data 265
 cluster-randomized trials 495, 497
 combining dichotomous and continuous
 outcome data 272

INDEX

cross-over trials 504, 507
 counts and rates 274
 data extraction 180–1
 forest plots 339
 non-randomized studies 423
 ordinal outcome data 272
 RevMan 265, 275, 339–40
see also inverse-variance meta-analysis
 GRADE 350, 361–7, 383
 non-randomized studies 427
 Overviews of reviews 620, 622, 623, 628–9
 GRADEprofiler software 344–6
 graphs *see* figures
 grey literature
 databases 106–7, 118, 145
 reporting bias 308–9
 gross domestic product (GDP) 468
 group-allocated studies *see* cluster-allocated
 studies

handsearching 107–8, 120
 harms *see* adverse effects
 hazard ratio 259, 275, 423
 headings 56
 health equity 597–8
 Health InterNetwork Access to Research
 Initiative (HINARI) 99, 109
 health promotion-specific databases 103
see also public health and health promotion
 health status 534–5
 Health Technology Assessment Database (HTA)
 111
 health-related quality of life (HRQOL) 533–6,
 538, 540, 542–3
 health-specific databases 102–5
 healthcare librarians 118–19
 heterogeneity 276–89
 addressing 278–80
 analysis plans 249, 286, 288
 baseline risk 288–9
 definitions 276–7
 dichotomous outcome data 267
 dose-response analyses 289
 economics evidence 469
 forest plots 338–9
 GRADE/quality of evidence 362, 365
 I-squared 278, 282
 identification and measurement 277–8
 interaction and effect modification 282
 meta-regression 284–8
 methods sections 62

- multi-arm studies 511–12
- non-randomized studies 412, 419, 423–4, 426
- Overviews of reviews 629
- rare events 523
- reporting bias 313, 318
- subgroup analyses 282–8
- tau-squared 281, 318, 338–9
- testing 277–8, 281
 - see also* random-effects method
- hierarchical models 519–20
- highly sensitive search strategies 135–9, 141–2
- HINARI *see* Health InterNetwork Access to Research Initiative
- historically controlled studies 393
- History tables 46–8, 55
- homogeneity *see* heterogeneity
- HRQOL *see* health-related quality of life
- HTA *see* Health Technology Assessment Database

- I-squared 278, 281
- ICC *see* intraclass correlation coefficients
- ICER *see* incremental cost-effectiveness ratio
- ICMJE *see* International Committee of Medical Journal Editors
- identifiers 73, 143, 157, 166
- implications for practice/research 67, 380–2
- imputations
 - change from baseline 270, 485–8
 - cluster-randomized trials 496
 - cross-over trials 503, 505–7
 - intention to treat 225–6, 484, 490–2
 - standard deviations 485–8
- IRMG *see* Information Retrieval Methods Group
- IMS *see* Information Management System
- incomplete outcome data 194, 219–26
 - attrition/drop-out 194, 220, 438
 - exclusions 194, 196, 200, 219–21
 - results sections 65
 - Risk of bias tool 195–196, 200, 203–4, 219–26
 - see also* intention to treat; missing data; selective outcome reporting
- incremental cost-effectiveness ratio (ICER) 457
- index terms *see* controlled vocabulary
- indirect comparisons 363, 513–15, 621, 630
- indirect evidence 362, 363–5
- individual patient data (IPD) 164, 547–58
 - benefits and limitations 549, 553, 555–6
 - collaborations 549, 550–1
 - confidentiality 550–1
 - data collection 164, 551–3
 - meta-analysis 520, 553–5
 - prospective meta-analyses 560–3
- individual patient data meta-analysis methods
 - group (IPD MA MG) 549–50, 555, 557
- inequalities 597–8
- Information Management System (IMS) 20–1
- Information Retrieval Methods Group (IRMG) 147, 407
- integrity of interventions 89, 159–60, 601
- intention to treat (ITT) 220–1, 488–93
- interaction 282
- interim analyses 231, 567–8
- International Committee of Medical Journal Editors (ICMJE) 309–10
- interpreting results 359–87
 - continuous outcome data 377–9
 - dichotomous outcome data 372–7
 - economics evidence 474
 - meta-regression 287–8
 - non-randomized studies 424–8
 - patient-reported outcomes 541–3
 - subgroup analyses 287–8
- interquartile ranges 176
- interrupted-time-series studies 393
- interventions
 - background sections 57
 - Characteristics of studies tables 337
 - data collection 157, 159–60
 - eligibility criteria 58–9, 86–7, 92
 - integrity 89, 159–60, 601
 - review questions 86–7, 92
- intraclass correlation coefficient (ICC) 496–8
- inverse-variance meta-analysis 264–5
 - continuous outcome data 268
 - dichotomous outcome data 265–7
 - fixed-effect method 264
 - random-effects method 266, 272–3, 275
 - rare events 521, 523
 - RevMan 275
 - see also* generic inverse-variance outcome data
- IPD *see* individual patient data
- IPD MA MG *see* individual patient data meta-analysis methods group
- IRMG *see* Information Retrieval Methods Group
- ITT *see* intention to treat

- Joanna Briggs Institute (JBI) 580, 582, 591
journals 107–13, 163
- kappa statistics 155–6, 169
- L'Abbé plots 342
- language
 bias 97, 298, 306–7
 restrictions 134
- last edit date 41
- last observation carried forward (LOCF) 225–6
- licensing 97–8
- location bias 298, 305–6
- LOCF *see* last observation carried forward
- log scales 176, 182, 259–60, 263, 271, 312
- log-rank statistics 180, 275
- main outcomes 88–9, 343
- main text sections *see* text sections
- maintenance of Cochrane reviews 31–49
 amendments 33, 34–7
 citation versions 33–6, 37–9
 conclusions changed 34, 37–8
 dates 39–41
 definitions 32–9
 editorial procedures 46
 feedback 48
 frequency 32
 History tables 46–8
 major changes 34, 35
 methods 45
 protocols 11–12, 33–6
 review questions 42–4, 93
 splitting reviews 44–5
 updates 33–4, 36, 37, 41–6
 What's new events 41, 46–7
 withdrawn reviews 17, 33, 46, 70
- major changes to protocols 34, 35
- Mantel-Haenszel methods 266, 282
 forest plots 338
 non-randomized studies 421
 rare events 521, 523
 RevMan 275, 339
 test for subgroup differences 284
- masking *see* blinding
- matching 420–1
- mean difference *see* difference in means;
 standardized mean difference
- measurement scales *see* scales
- measures of agreement 155–6, 169
- medians 176, 340
- MEDLINE 98–102, 118
 abstracts of Cochrane reviews 55
 adverse effects 440–1
 CENTRAL 119–21
 citation versions 33–5
 economics evidence 460
 handsearching 107–8
 identifiers 73
 non-randomized studies 404, 406
 patient-reported outcomes 536, 538
 qualitative research 579
 reporting bias 97, 305, 308
 searching for reviews 111–12
 searching for studies 125–31, 134–42
- meta-analysis 6, 243–96, 481–529
 benefits and limitations 246–7
 baseline risk 288–9
 Bayesian methods 210, 518–19
 cluster-randomized trials 495–6, 497
 cross-over trials 502–7
 data collection 162
 data types
 continuous outcome data 268–72, 290
 counts 273–4, 521
 dichotomous outcome data 265–8, 271–2,
 520–3
 generic inverse-variance outcome data 265
 O – E and Variance data 266, 274–5, 555
 ordinal outcome data 272–3
 rate data 273–4
 time-to-event data 274–5
 dose-response analyses 289
 economics evidence 470–1
 effect measures 250–9, 279–80
 difference in means 268–72
 odds ratio 265–8, 271–2
 risk difference 265–8
 risk ratio 265–8
 standardized mean difference 256–7,
 268–9, 271–2
 fixed-effect method 264, 279
 forest plots 76, 337–40
 heterogeneity 276–89
 hierarchical models 519–20
 indirect comparisons 513–15
 individual patient data 520, 553–5
 interpreting results 369–79
 inverse-variance 264–5
 Mantel-Haenszel methods 266, 282
 meta-regression 284–9
 methods sections 62

- missing data 482–93
- multi-arm studies 508–12
- multiple analyses 210, 226–30, 516–18, 541
- multiple-treatments 510–11, 513–16, 621
- non-randomized studies 413, 419–24
- patient-reported outcomes 541–3
- Peto method 266, 275, 521, 523
- planning 244–6
- precision 246, 264
- pre-specification 249, 286, 288, 516–7
- principles 263–4
- prospective 564–5, 567–8
- protocols 248–9
- random-effects methods 263–5, 279–82
- rare events 520–3
- results sections 65–6, 351
- RevMan 244, 248, 265, 272–6, 279, 281–4
- risk of bias 188–90, 206–10, 247
- scales 269, 272–3
- sensitivity analyses 289–92, 319–21
- skewed data 270–1
- standard errors 256–7, 268–9, 271–2
- statistical test 264, 338–9
- subgroup analyses 282–8
- vote counting 276
- weights 263–4, 266, 269, 282, 320
- meta-epidemiology 190, 208
- meta-regression 284–9
 - baseline risk 288–9
 - figures 342
 - interpreting results 287–8
 - risk of bias 208
 - study characteristics 285–7
- methods sections 58–63, 618–21
- MID *see* minimally important difference
- minimally important difference (MID) 371, 542
- missing data 482–8
 - conditional outcomes 492–3
 - general principles 483–4
 - individual patient data 552, 556
 - intention to treat 488–93
 - methods sections 62
 - sensitivity analyses 290–1, 484, 491–2
 - standard deviations 485–8
 - types 482–3
 - see also* imputations; incomplete outcome data; selective outcome reporting
- mixed methods approach 573, 575
- MTM *see* multiple-treatments meta-analysis
- multi-arm studies 262, 508–13
 - factorial trials 508, 512–13
 - heterogeneity 511–12
 - meta-analysis 508–12
 - methods sections 62
 - risk of bias 509–10
- multi-centre trials 561
- multiple
 - analyses 210, 226–30, 516–18, 541
 - body parts 262
 - intervention groups 62, 262, 508–13
 - publication 298, 304–5
 - reports 152, 168–9
 - treatment attempts 261–2
- multiple-treatments meta-analysis (MTM) 510–11, 513–16, 621
- narrative summaries 244–5, 468–70
- narrow questions 91–3
- National Library of Medicine (NLM) 100–1, 119–21, 123, 127
- network meta-analysis *see* multiple-treatments meta-analysis
- new citation versions 33–6, 37–9
- Newcastle-Ottawa Scale 418, 424
- next stage expected date 41, 54
- NHS Economic Evaluation Database (NHS EED) 460–2, 463, 465, 470
- NLM *see* National Library of Medicine
- NNH *see* number needed to treat
- NNT *see* number needed to treat
- no longer updated date 41
- Non-Randomized Studies Methods Group (NRS MG) 392–4, 396, 400, 403, 406–7, 418, 423, 428
- non-randomized studies (NRS) 391–432
 - adjusted estimates 412, 416–7
 - adverse effects 397, 400, 427, 438, 443–5
 - aetiological research questions 399
 - benefits and limitations 392–5, 397
 - confounding 395, 397, 412, 416–17, 420–2
 - data collection 407–11
 - designs and design features 392–5, 398, 400–3
 - eligibility criteria 396–403, 407, 425
 - generic inverse-variance data 420
 - GRADE/quality of evidence 362, 366–7, 427
 - heterogeneity 412, 419, 423–4, 426
 - inclusion with randomized trials 394, 396–7, 405–8
 - interpreting results 424–8
 - meta-analysis 413, 419–24
 - precision 397–8

- non-randomized studies (NRS) (*Continued*)
 - protocols 395–6, 414–15
 - public health and health promotion 594, 595
 - reporting bias 90, 404
 - resources and guidance 399–403, 406–7, 408–11, 414–18, 420–4, 427–8
 - risk of bias/quality 392, 394, 395, 397–9, 412–20, 425–6
 - searching 404–7
 - selecting studies 407–11
 - selection bias 395, 416
 - strength of evidence 426–7
- NRS *see* non-randomized studies
- NRS MG *see* Non-Randomized Studies Methods Group
- number needed to treat (NNT) 250, 254, 267–8, 373–7, 379
- nursing-specific databases 103–4
- O – E and Variance data 266, 274–5, 555
 - see also* time-to-event data
- objectives sections 57–8, 614, 618
- observational studies *see* non-randomized studies
- odds ratio (OR) 250–5
 - cluster-randomized trials 497
 - confidence intervals 369–70
 - data extraction 181–2
 - forest plots 338
 - funnel plots 314–6, 318
 - interpreting results 373–7
 - log scales 182, 259–60, 263, 312
 - meta-analysis 265–8, 271–2
 - non-randomized studies 421, 423
 - ordinal outcome data 257–8, 272–3
 - rare events 521–3
 - RevMan 339–40
 - standardized mean difference 271–2, 378–9
 - Summary of findings tables 346v7, 350
- ongoing studies 72, 73, 113–18
- ordinal outcome data 250, 257–8
 - data extraction 178
 - meta-analysis 272–3
 - sensitivity analyses 291
- OR *see* odds ratio
- other outcome data 75, 271, 275, 337, 340–1
- outcomes
 - adverse effects 90, 433–48
 - change from baseline 172, 269–70
 - Characteristics of studies tables 337
 - Data and analysis section 74–5
 - data collection 157, 161–2
 - economics evidence 456–7
 - eligibility criteria 84, 87–90
 - GRADE/quality of evidence 360–1
 - grouping in Risk of bias tool 195
 - main 59, 88–9, 343
 - methods sections 59
 - missing *see* incomplete outcome data
 - multiple 516–7
 - patient-reported 531–545
 - primary 59, 89
 - reporting bias *see* selective outcome reporting
 - review questions 87–90
 - risk of bias summarization 205–6, 364
 - secondary 59, 89
 - Summary of findings tables 59, 88–9, 343–4, 348–9
 - see also* continuous outcome data; count data; dichotomous outcome data; ordinal outcome data; other outcome data; rate data; time-to-event data
- outcome reporting bias *see* selective outcome reporting
- overview plots *see* forest top plots
- Overviews of reviews 7, 607–31
 - abstracts 615–16
 - acknowledgements 624
 - analyses 615, 619–21
 - comparison with intervention reviews 614–5
 - conclusions 616, 623–4
 - data collection 614, 619
 - declarations of interest 624
 - definition 607
 - discussion sections 622–3
 - eligibility criteria 609–12, 614, 618–19, 625
 - figures 630
 - format 613–30
 - GRADE/quality of evidence 620, 622, 623, 628–9
 - implications for intervention reviews 88, 93
 - methods sections 618–22
 - new material and analyses 612, 613, 620–1
 - objectives sections 618
 - organizational issues 608, 613
 - plain language summary 616
 - protocols 608, 624
 - quality of included reviews 613, 614, 620, 621
 - rationale 608, 609–12
 - references 625
 - results sections 621–2

- searching 614, 619
- tables 625–9
- text sections 616–24
- titles 613, 615
- updates 613
- P values 370–2
 - contour-enhanced funnel plot 313–5
 - data extraction 174–5, 181–2
 - funnel plot asymmetry test 315–6
 - heterogeneity test 277–8
 - meta-analysis test 264
 - multiple analyses 516–17
 - selection models 322
- paired t-tests 501–2
- pairwise comparisons 245, 248, 508–11
- parallel group trials 498
- partial economic evaluations 451
- participants
 - background sections 58
 - Characteristics of studies tables 336
 - data collection 157–9
 - eligibility criteria 58, 85–6, 92
 - responsiveness 160
 - review questions 85–6, 92
- patient preferences 369
- Patient-Reported Outcomes Methods Group (PRO MG) 531, 533, 543
- patient-reported outcomes (PROs) 531–45
 - assessment and description 539
 - comparability 540–1
 - definitions 532–3, 534
 - importance 533–4
 - interpreting results 541–3
 - measurement of change 538
 - quality of life 533–6, 538, 540, 542–3
 - searching 538–9
 - validity of instruments 537–8
- peer review 22, 303
- performance bias 195
- permission to publish 25–6
- per-protocol analysis 221, 489
- Peto method 266, 275, 521, 523
- pharmaceutical industry trials registers 116–17
- pharmacology-specific databases 103
- PHHP *see* public health and health promotion
- Phillips checklist 465
- PICO acronym 83, 84, 129
- placebo-controlled trials 218
- plain language summaries 55, 355–6, 616
- plots *see* figures; forest plots; funnel plots
- PMA MG *see* Prospective Meta-analysis Methods Group
- PMAs *see* prospective meta-analyses
- pooled estimates *see* meta-analysis
- population average effect 423
- post hoc* analyses 12, 286, 288, 351
- PPP *see* Purchasing Power Parities
- pre-specification
 - meta-analysis methods 249, 286, 288, 516–7
 - non-randomized studies 396, 415–6
 - outcomes 161
 - review methods 6, 84–5
 - selective outcome reporting 201
- precision
 - confidence intervals 370
 - funnel plots 310
 - GRADE/quality of evidence 362, 365
 - meta-analysis 246, 264
 - non-randomized studies 397–8
 - risk of bias 189, 206, 233
 - searching 130, 136–9
- preparation of Cochrane reviews 11–30
 - advisory groups 19–20
 - commercial sponsorship 26–8
 - consumer involvement 18–19
 - declarations of interest 26–8, 69, 624
 - editorial procedures 21–2, 46
 - format of Cochrane reviews 12–16
 - funding 24
 - logistics 13–24
 - motivation 13
 - permission to publish 25–6
 - protocols 11–12, 13, 17
 - publication in journals and books 24–6
 - resources 22–4, 427–8, 434, 436, 550, 562, 576
 - review teams 17–20
 - software 20–1, 52, 344–6
 - timeline 23, 24
 - topic and scope 13, 16–17
 - training 21
- presentation of results *see* results sections; Summary of findings tables
- primary outcomes 59, 89, 201
- PRO MG *see* Patient-Reported Outcomes Methods Group
- PROGRESS acronym 597–8
- proportional odds model 257, 272–3
- PROs *see* patient-reported outcomes

- prospective meta-analyses (PMAs) 559–70
 - collaborations 562–3
 - data collection 564, 566–7
 - definitions 559–61
 - eligibility criteria 559–61, 564–5
 - meta-analysis 564–5, 567–8
 - multi-centre trials 561
 - protocols 563–6
- Prospective Meta-analysis Methods Group (PMA MG) 559, 562, 568
- prospective trial registration 297
- protocol information 52–5
- protocols
 - amendments 34–5
 - citation versions 33–4, 35–6
 - differences with reviews 69–70
 - economics evidence 453, 462
 - first published date 54
 - major change 34–36
 - meta-analysis 248–9
 - multiple analyses 481, 517
 - non-randomized studies 395–6, 414–15
 - outline 13–14
 - Overviews of reviews 624
 - prospective meta-analyses 563–6
 - rationale 11–12
 - registration 17
- proximity operators 133–4
- psychiatry-specific databases 104
- psychology-specific databases 104, 107
- PsycINFO 104, 107, 579
- public health and health promotion (PHHP) 593–606
 - applicability 601–3
 - context 599–600
 - ethics 597–8
 - inequalities 597–8
 - qualitative research 574–5
 - risk of bias/quality 595–7
 - searching 594–5, 596
 - study design 594
 - sustainability 600–1
 - transferability 601–3
- publication bias 298–304
 - causes 303–4
 - direct and indirect evidence 299–300
 - GRADE/quality of evidence 362, 365–6
 - multiple 298, 304–5
 - review questions 90
 - time lag bias 298, 300–3
 - trial registries 309–10
 - see also* reporting bias
- publication policies 24–6, 549, 564, 566
- published notes 70
- PubMed 100, 143–4
 - see also* MEDLINE
- Purchasing Power Parities (PPP) 468
- QALY *see* quality-adjusted life years
- QOL *see* quality of life
- QRMG *see* Qualitative Research Methods Group
- qualitative research 571–91
 - critical appraisal/quality 580–1, 590–1
 - definitions 572–3
 - directly observed therapy 576–9
 - eligibility criteria 577
 - implementation of interventions 574–6, 578
 - integration with quantitative research 582–3, 589–90
 - mixed methods approach 573, 575
 - public health and health promotion 594–5, 596
 - randomized trials 575–6
 - resources 576, 587–91
 - review questions 574
 - searching 575, 577, 579–80, 589
 - strategies for addressing 573–6
 - synthesis 575, 576–83, 589–90
- Qualitative Research Methods Group (QRMG) 572, 583–4
- quality
 - adverse effects 442–5
 - economics evidence 463–7, 470
 - evidence *see* GRADE
 - interventions 160
 - non-randomized studies 392, 394, 395, 397–9, 412–20, 425–6
 - Overviews of reviews 613, 614, 620–3, 628–9
 - public health and health promotion 595–7
 - qualitative research 580–1, 590–1
 - scales 190–2
 - weights 191, 210
 - see also* risk of bias
- quality of life (QOL) 533–6, 538, 540, 542–3
- quality-adjusted life years (QALY) 452, 457
- quantitative synthesis *see* meta-analysis
- quasi-randomized studies 122, 213, 392, 401, 409, 413

- random-effects methods 263–5, 279–82
 - confidence intervals 370
 - dichotomous outcome data 266–7, 523
 - forest plots 338–9
 - multi-arm studies 511–12
 - reporting bias 319–21
 - RevMan 265, 267–9, 275, 282
 - sensitivity analyses 291, 319–21
 - tau-squared 281, 318, 338–9
- randomization 193, 210–15, 552–3
- randomized controlled trial (RCT) 119–23, 126, 136–9
- randomized trials
 - adverse effects 434
 - GRADE/quality of evidence 361–6
 - inclusion with non-randomized studies 394, 396–7
 - public health and health promotion 594, 595
 - qualitative research 575–6
 - review questions 90–1
 - risk of bias 193–4, 210–34
 - searching 135–9
- ranges 176
- rare events 520–3
- rate data 250, 258
 - data extraction 178–9
 - meta-analysis 273–4
- ratio measures 182, 252–4, 350, 372–3
- RCT *see* randomized controlled trial
- RD *see* risk difference
- references 72–4
 - managing 142–4
 - Overviews of reviews 625
 - searching 110–11, 113
- regional databases 101–2
- regression models 420, 421–2
- re-inclusions 221
- related terms 131–2
- relative effects *see* ratio measures
- relative risk *see* risk ratio
- relative risk reduction (RRR) 372–3
 - see also* risk ratio
- re-occurring events 261
- repeated observations 261
- reporting bias 297–333
 - avoidance 308–10
 - citation bias 298, 306
 - definitions 298
 - detection 310–23
 - economics evidence 472–3
 - funnel plots 310–19
 - grey literature 308–9
 - heterogeneity 313, 318
 - individual patient data 556
 - language bias 298, 306–7
 - location bias 298, 305–6
 - methods sections 62, 249
 - non-randomized studies 90, 404
 - searching 97, 305–6, 308–10
 - selective outcome reporting 194, 226–30, 298, 307–9
 - sensitivity analyses 319–23
 - trial registries 309–10
 - unpublished studies 308–9
 - see also* publication bias; risk of bias
- reports *see* study reports
- resources
 - economics evidence 450–1, 470–1
 - information sources 98–128, 439–40, 450–2, 596
 - preparation of Cochrane reviews 22–4, 427–8, 434, 436, 550, 562, 576
- restricted randomization 212–13
- results sections 63–66, 351–2, 621–2
- retracted publications 134–5
- review information 52–5
- Review Manager (RevMan) software 20–1
 - cluster-randomized trials 495–7
 - cross-over trials 502
 - data entry 170–1, 175, 180–2
 - dates 39, 54–5
 - figures 76–7, 341–2
 - forest plots 338–40
 - format of Cochrane reviews 12–13, 52
 - headings 56
 - identifiers 166
 - indirect comparisons 514
 - individual patient data 555
 - meta-analysis 244, 248, 265, 272–6, 279, 281–4
 - non-randomized studies 420
 - funnel plots 312
 - P values 371–2
 - Risk of bias tool 202–4, 207–8
 - Summary of findings tables 344–6
- review questions 83–94
 - broad versus narrow 91–3
 - changing 44, 93
 - eligibility criteria 84–5, 91
 - interventions 86–7, 92

- review questions (*Continued*)
 - outcomes 87–90
 - participants 85–6, 92
 - studies 90–1
 - Summary of findings tables 343
- review teams 17–20
- RevMan *see* Review Manager
- risk of bias 187–241
 - adverse effects 442–5
 - allocation concealment 193, 211, 214–17
 - assessment tools 190–3
 - see also* Risk of bias tool
 - baseline imbalance 231–2
 - blinding 193–4, 217–9
 - cluster-randomized trials 494–5
 - continuous outcome data 200, 223–4, 227
 - cross-over trials 499–501
 - data collection 157–8, 192–3
 - data extraction 169
 - definitions 188–9
 - design-specific 230
 - dichotomous outcome data 200, 208, 223, 227
 - differential diagnostic activity 232
 - direction and magnitude 204–5
 - early stopping 231
 - economics evidence 463–7, 470
 - empirical evidence 190, 204, 211–12, 214–15, 217–18, 221, 226–7
 - figures/graphs 76–7, 202–4, 207
 - forest plots 207
 - funding 233
 - GRADE 362–4, 365–6
 - incomplete outcome data 194, 219–26
 - meta-analysis 188–90, 206–10, 247
 - methods sections 61
 - multi-arm studies 509–10
 - non-randomized studies 392, 394, 395, 397–9, 412–20, 425–6
 - other sources 233–4
 - Overviews of reviews 620, 623, 627
 - precision 189, 206, 233
 - presentation of assessments 202
 - public health and health promotion 595–7
 - quality 189–90
 - randomized trials 193–4, 210–34
 - rare events 523
 - reported 191
 - results sections 64–7
 - scales 190–2, 202
 - sensitivity analyses 209
 - sequence generation 193–8, 203, 210–14
 - summary assessments 202–6, 363–4
 - Summary of findings tables
 - tables 71, 202–3
 - time-to-event data 222
 - updates and amendments 42, 45
 - see also* reporting bias
- risk difference (RD) 250–1, 254–5
 - funnel plots 318–19
 - interpreting results 372–375
 - meta-analysis 265–8
 - rare events 522–523
 - Summary of findings tables 346–7
- Risk of bias tool 194–202
 - allocation concealment 196, 198–9, 203–4
 - blinding 195–196, 199, 203–4, 217–19
 - descriptions 197
 - incomplete outcome data 195–196, 200, 203–4, 219–26
 - judgements 197–202
 - other sources 194, 233–4
 - RevMan 202–4, 207–8
 - selective outcome reporting 195–196, 201, 203–4, 228–30
 - sequence generation 196, 197–8, 203–4
 - unclear 197–202, 207, 213–14
- risk ratio (RR) 250–5
 - funnel plots 318–19
 - interpreting results 372–4, 376–7
 - meta-analysis 265–8
 - rare events 521–3
 - Summary of findings tables 346–7
- RR *see* risk ratio
- RRR *see* relative risk reduction
- scales 250, 257–8
 - data extraction 157, 161, 178
 - meta-analysis 269, 272–3
 - risk of bias/quality 190–2, 202
 - see also* continuous outcome data; log scales; ordinal outcome data
- SCHARP software 555
- SCI *see* Science Citation Index
- Science Citation Index (SCI) 33, 35, 38, 55, 352
- scope of review questions 91–3
- searching 95–150
 - abstracts 98, 110, 143, 145, 406, 441–2
 - adverse effects 439–42
 - dates 40–1, 42, 54
 - documenting 59–60, 144–6
 - economics evidence 459–62
 - eligibility criteria 128

- managing references 142–4
- methods sections 59–60, 145–6
- non-randomized studies 404–7
- Overviews of reviews 614, 619
- patient-reported outcomes 538–9
- planning 118–28
- public health and health promotion 594–5, 596
- qualitative research 575, 577, 579–80, 589
- references 110–11, 113
- reporting bias 97, 305–6, 308–10
- results sections 63, 145
- sources 98–118
 - bibliographic databases 98–107
 - Cochrane Library 99–100, 119, 121, 124–6, 133–4
 - EMBASE 111–12, 125–31, 139
 - grey literature 106–7, 118, 145
 - journals 107–13
 - MEDLINE 111–12, 125–31, 134–42
 - ongoing/unpublished studies 113–18
- strategies 128–42
 - Boolean operators 132–3, 141
 - examples 140–1
 - filters 135–9
 - proximity operators 133–4
 - restrictions 134
 - search filters 135–9
 - sensitivity and precision 130, 136–9, 141–2
 - service providers/search interfaces 129
 - structure 129
 - subject terms 130–2
 - updating 139–41
- titles 98, 406, 441–2
- Trials Search Co-ordinators 96–8, 102, 108, 118–19, 124–5, 143, 146
- secondary outcomes 59, 89
- selection bias 195, 211, 215
 - funnel plots 313
 - non-randomized studies 395, 412, 416
 - see also* selective outcome reporting
- selecting studies 152–6
- selective outcome reporting 194, 226–30, 298, 307–9
 - results sections 65
 - Risk of bias tool 195–196, 201, 203–4, 228–30
- sensitivity
 - analyses 289–92
 - cluster-randomized trials 498
 - cross-over trials 505–8
 - individual patient data 556
 - methods sections 63
 - missing data 484, 491–2
 - non-randomized studies 423
 - reporting bias 319–23
 - risk of bias 209
 - search strategy 130, 136–9, 141–2
 - sequence generation 193–8, 203, 210–14
 - results sections 65
 - Risk of bias tool 196, 197–8, 203–4
 - service providers 129
 - simple randomization 212
 - skewed data 176, 270–1
 - small study effects 312–13, 317, 319–24, 404
 - SMD *see* standardized mean difference
 - SMG *see* Statistical Methods Group
 - social healthcare-specific databases 104
 - social science-specific databases 104
 - socio-economic data 597–8
 - software 20–1, 52, 344–6
 - sources of support 26–7, 77
 - splitting reviews 44–5, 91, 93
 - standard deviations
 - cross-over trials 503, 506
 - data extraction 171, 173–7
 - missing 485–8
 - standardized mean differences 256, 269–270, 379
 - standard errors
 - cluster-randomized trials 497
 - cross-over trials 506–7
 - data extraction 171, 173–5, 181–2, 278–9
 - meta-analysis 264, 270, 274
 - standardized mean difference (SMD) 256–7, 377–9
 - change from baseline 270
 - cluster-randomized trials 493
 - cross-over trials 504–5
 - funnel plots 318–19
 - interpreting results 377–9
 - meta-analysis 256–7, 268–9, 271–2
 - patient-reported outcomes 541, 542
 - statistical
 - heterogeneity *see* heterogeneity
 - significance 371–2
 - tests
 - funnel plot asymmetry 314–9
 - heterogeneity 277–8, 338–9
 - meta-analysis 264, 338–9
 - subgroup differences 284, 338–9
 - Statistical Methods Group (SMG) 292, 324

- Steering Group 28
- stratification 213, 420, 421
- stratified randomization 213
- structure *see* format of Cochrane reviews
- studies awaiting classification 64, 71, 73
- study reports
 - data collection 163
 - data extraction 167–70
 - eligibility criteria 97, 152
- studies
 - Characteristics of studies tables 336
 - data collection 157–8
 - eligibility criteria 58, 90–1
 - review questions 58–60, 90–1
 - selecting 152–6
- subgroup analyses 282–8
 - Data and analysis section 74–5
 - individual patient data 554–5
 - interpreting results 287–8
 - methods sections 62
 - study characteristics 285–7
 - test for differences 284, 338–9
- subheadings 56
- subject-specific databases 102–5
- subject-specific trials registers 116, 124–5
- summary assessments 202–6
- Summary of findings tables 72, 342–50
 - detailed contents 348–50
 - GRADE/quality of evidence 342–4, 350, 360–7
 - outcome selection 88–9, 343–4
 - Overviews of reviews 620, 626–7, 629
 - patient-reported outcomes 533
 - software 344–6
 - statistical considerations 346–7, 374
 - templates 344
- survival data *see* time-to-event data
- sustainability 600–1
- synonyms 131–2
- synthesis
 - qualitative 575, 576–83, 589–90
 - quantitative *see* meta-analysis
- systematic review 6
- t values 174–5
- tables of contents (TOC) services 109–10
- tables 70–2
 - Additional 72, 234, 350–1, 468, 539
 - Characteristics of excluded studies 64, 71, 154
 - Characteristics of included studies 63–4, 70, 336–7, 468
 - Characteristics of ongoing studies 64, 72
 - Characteristics of studies awaiting classification 64, 71
 - Overviews of reviews 620, 625–9
 - Risk of bias 71, 202–3
 - Summary of findings 72, 342–350
- tau-squared 281, 318, 338–9
- tests *see* statistical tests
- text sections 55–70, 616–24
 - authors' conclusions sections 67
 - background sections 56–7
 - discussion sections 66–7
 - methods sections 58–63
 - objectives sections 57–8
 - Overviews of reviews 616–24
 - results sections 63–6, 351–2, 468–70
- text words 130–1, 441–2, 539
- thesaurus terms *see* controlled vocabulary
- theses databases 106
- time lag bias 298, 300–3
- time-to-event data 250, 259
 - confidence intervals 370
 - counts 179
 - data extraction 179–80
 - individual patient data 549, 554, 555
 - meta-analysis 274–5
 - risk of bias 222
 - sensitivity analyses 290
- timeline for Cochrane reviews 23, 24
- titles 52–3
 - adverse effects 441–2
 - non-randomized studies 406
 - Overviews of reviews 613, 615
 - results sections 348, 355–6
 - searching 98, 406, 441–2
 - selecting studies 153
- TOCs *see* tables of contents
- training 21
- transferability 601–3
- transformations 176
- treatment effects 61, 244
- trials registers 114–17, 124–5, 309–10
- trials results registers 116–17
- Trials Search Co-ordinators (TSC) 96–8, 102, 108, 118–19, 124–5, 143, 146
- trim and fill method 321
- TRIP *see* Turning Research into Practice
- truncations 131–2
- TSC *see* Trials Search Co-ordinators

INDEX

649

- Turning Research into Practice (TRIP) 111
- unclear risk of bias 197–202, 207, 213–14
- unit-of-analysis errors 260–2, 493, 495, 502
- unpublished studies 113–18, 308–9
- unrestricted randomization 212
- up-to-date reviews 40, 54
- updates 33–4, 36, 37, 40–7
- methods sections 63
 - Overviews of reviews 613
 - searching 139, 141
- validation of instruments 537–9
- validity *see* risk of bias
- variant spellings 131–2
- vote counting 276
- web searching 113
- weighted mean difference (WMD) 256
- weights
- meta-analysis 263–4, 266, 269, 282, 320
 - quality 191, 210
- well-being 532, 534
- What’s new events 41, 46–7, 55
- WHO *see* World Health Organization
- wildcards 131–2
- WinBUGS software 518–19
- withdrawals *see* incomplete outcome data
- WMD *see* weighted mean difference
- World Health Organization (WHO) 114
- zero frequencies 521–2

This index was prepared by Neil Manley, and edited by Julian Higgins.